Contract research firm Parexel is said to garner takeover interest from Private equity giant EQT and a consortium of three other buyout majors.
A consortium of Cinven, Centerbridge and GTCR is working on a bid for the contract research organization, according to traders, who cited a Bloomberg report.
Parexel is said to have received interest from about 10 parties.
Bloomberg reported in April Parexel’s PE owner Pamplona Capital Management was exploring a sale of the company in a deal that could value Parexel at about $9B including debt.
The potential sale comes after some other big deals for CROs earlier this year including Thermo Fisher’s (NYSE:TMO) planned $17B deal for PPD (NASDAQ:PPD) and Icon PLC’s agreement to purchase PRA Health (NASDAQ:PRAH) for about $12B.
Source: Seeking Alpha
Can’t stop reading? Read more
EQT leads $5.5bn Galderma share sale in record Swiss secondary exit
EQT leads $5.5bn Galderma share sale in record Swiss secondary exit EQT and its co-investors have...
CVC reports record performance as €205bn private markets platform expands
CVC reports record performance as €205bn private markets platform expands CVC Capital Partners...
Brookfield explores $1.3bn acquisition of EQT and PAI-backed World Freight Company
Brookfield explores $1.3bn acquisition of EQT and PAI-backed World Freight Company Brookfield...